News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Market source Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
This article analyzes Anika Therapeutics Inc. (ANIK) using AI models, highlighting strong sentiment across all horizons and significant upside potential due to the absence of resistance levels above the current price. It presents three distinct institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for …
Zacks Research has upgraded Anika Therapeutics (NASDAQ:ANIK) to a "strong-buy" rating. This upgrade follows the company's strong quarterly earnings, where EPS of $0.42 significantly beat the $0.03 consensus, and revenue of $32.61 million also exceeded expectations. Institutional investors hold a substantial portion of the …
Image source: The Motley Fool. DATE Wednesday, July 29, 2026 at 8:30 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Stephen D. GriffinSenior Vice President, Chief Accounting Officer, and Treasurer - Ian W. McLeodExecutive Director, Corporate Development and Investor Relations - Matthew …
This article provides comprehensive financial data for Anika Therapeutics, Inc. (ANIK), including its current stock price, historical performance, and key financial metrics. It details the company's orthopedic products and services, analyst ratings, and comparative data with other companies in the drug manufacturing industry. The …
An individual holder of Anika Therapeutics, Inc. (ANIK) plans to sell 16,864 shares of common stock on NASDAQ, with an aggregate market value of $355,255.47 as of August 7, 2026, according to a Form 144 filing. The filing also notes recent activity including an …
Gary Fischetti, a Director at Anika Therapeutics Inc (ANIK), recently purchased 2,000 shares at $20.53 each, increasing his total holdings to 54,015 shares. This transaction, valued at approximately $41,060, follows a trend of insider buying at the company, with 3 insider buys and no …
Anika Therapeutics Director Gary Fischetti purchased 1,000 shares of ANIK stock for $20.75 each, increasing his direct ownership to 53,015 shares. This transaction follows strong quarterly earnings where Anika reported $0.42 EPS and $32.61 million in revenue, both exceeding analyst expectations. Despite institutional investors …
Anika Therapeutics reported strong Q2 earnings, with record commercial and international revenue and significantly improved gross margins and adjusted EBITDA. The company raised its full-year guidance for revenue growth and adjusted EBITDA margin, despite acknowledging regulatory uncertainties for some products and potential quarterly variability …
Anika Therapeutics Inc. (ANIK) reported mixed results for Q1 2025, with commercial channel revenue up 18% and regenerative solutions growing 33%, driven by the Integrity implant system. Strategic initiatives and cost-saving measures proved effective, with anticipated US approvals for Halofast and Singal expected to …
This article reports on Anika Therapeutics' significant stock gain of 29%. The rise in stock price has benefited company insiders who engaged in recent trades.
Vanguard Capital Management LLC has reported a 4.95% beneficial ownership stake in Anika Therapeutics Inc (ANIK), amounting to 659,216 shares as of June 30, 2026. The filing indicates that Vanguard holds sole voting power over 87,103 shares and sole dispositive power over all 659,216 …
B. Riley has increased its price target for Anika Therapeutics (ANIK) to $21 from $18, while reaffirming its Buy rating on the stock. This adjustment reflects a positive outlook on the company, concurrent with Barrington also raising its price target to $21 and maintaining …
Anika Therapeutics Inc (ANIK) reported record Q2 2026 results, including a 17% increase in commercial channel revenue, a 65% gross margin, and record international revenue of $12.6 million. Adjusted EBITDA reached $7.1 million, and the company raised its full-year 2026 guidance. Despite these positive …
This article reports that Anika Therapeutics' adjusted earnings per share (EPS) for the second quarter were 42 cents. The headline provides the key financial performance indicator for the company.
This press release from Anika reports their second quarter 2026 financial results. The document (although not provided) would contain key financial metrics and performance highlights for the period, offering insight into the company's fiscal health and operational achievements.
Anika Therapeutics, Inc. reported a significant turnaround in Q2 2026, with adjusted earnings of $0.42 per share, exceeding expectations by 625.0%. The company's revenue increased by 16.0% to $32.6M, driven by strong growth in both its Commercial and OEM channels. This return to profitability …
Anika Therapeutics reported Q2 2026 results that significantly exceeded analyst expectations, with adjusted earnings of $0.42 per share and revenue of $32.6 million. The company's shares surged on the news, driven by a successful operational transformation leading to expanded gross margins of 65% and …
Anika Therapeutics reported strong Q2 2026 results, with revenue reaching $32.6 million, a 16% year-over-year increase, and a gross margin of 65%. The company achieved a net income of $3.3 million and adjusted diluted EPS of $0.42. Management raised its full-year 2026 revenue and …
This article provides a second-quarter earnings snapshot for Anika. It contains no financial details or further information about the company's performance. The article is exceptionally brief, offering only a title without substantive content.
Anika Therapeutics reported a rise in its second-quarter revenue, leading the company to subsequently lift its financial outlook for 2026. This positive performance and improved forecast were highlighted in a Reuters news brief accessible via TradingView.
An article by Stock Traders Daily's Quantitative Research Desk suggests that Anika Therapeutics Inc. (NASDAQ: ANIK) is facing weak near and mid-term sentiment, despite a positive long-term outlook. The analysis highlights a 34.4:1 risk-reward short setup, projecting a 10.9% downside risk versus a 0.3% …
This article provides a comprehensive stock analysis of Anika Therapeutics Inc (ANIK) by TradingKey. It highlights the company's strong fundamentals, high growth potential, and fair valuation within the Healthcare Equipment & Supplies industry. The analysis also notes high institutional ownership and a "Strong Buy" …
This article provides a detailed revenue breakdown for Anika Therapeutics Inc (ANIK) by business segment and geographical region. For the fiscal year 2025, the company's revenue was primarily driven by its OEM Channel and Commercial Channel. The United States contributed the largest portion of …
Anika Therapeutics (ANIK) recently filed a proxy summary detailing proposed changes to its 2017 Omnibus Incentive Plan, particularly Proposal 4, which faces dilution concerns despite board approval. The plan continues to use a fungible design for executive compensation, assigning higher cost to full-value awards. …
Anika Therapeutics (ANIK) presented a summary of their 2026 CG Musculoskeletal Conference, detailing their strategy to accelerate growth through commercial momentum, product pipeline advancement, and operational discipline. The company highlighted its strong financial position, robust product portfolio in OA pain management and regenerative solutions, …
BlackRock Portfolio Management LLC has filed an amended ownership report for Anika Therapeutics Inc. common stock, disclosing a 4.1% beneficial ownership stake, totaling 544,710 shares. The firm holds sole voting power over 520,622 shares and sole dispositive power over all 544,710 shares. No single …
Anika Therapeutics announced it has expanded its revolving credit facility with Bank of America, N.A. The Fifth Amendment establishes a $50 million senior revolving line of credit with a new maturity date of July 10, 2031, and includes an option to increase total commitments …
Anika Therapeutics, Inc. (NASDAQ: ANIK) announced it will release its second quarter 2026 financial results before market open on Wednesday, July 29, 2026. This will be followed by a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can …
Search by ticker symbol or company name and select a result to open its chart.